GetTopicDetailResponse(id=974294121a5, topicName=過繼細(xì)胞治療, introduction=過繼細(xì)胞治療, content=null, image=null, comments=3, allHits=1210, url=https://h5.medsci.cn/topic?id=94121, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=18610, tagList=[TagDto(tagId=18610, tagName=過繼細(xì)胞治療)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2242380, encodeId=ed2222423805b, content=<a href='/topic/show?id=974294121a5' target=_blank style='color:#2F92EE;'>#過繼細(xì)胞治療#</a> <a href='/topic/show?id=67cd829955f' target=_blank style='color:#2F92EE;'>#腫瘤浸潤淋巴細(xì)胞#</a>, objectTitle=基于T細(xì)胞的TILs腫瘤免疫治療, objectType=article, longId=854171, objectId=6a068541e1ba, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241210/1733820472457_8538692.png, objectUrl=/article/show_article.do?id=6a068541e1ba, replyNumber=0, likeNumber=31, createdTime=2024-12-14, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=6a068541e1ba, moduleTitle=基于T細(xì)胞的TILs腫瘤免疫治療, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=6a068541e1ba)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2018112, encodeId=a210201811276, content=<a href='/topic/show?id=974294121a5' target=_blank style='color:#2F92EE;'>#過繼細(xì)胞治療#</a>, objectTitle=CLIN CANCER RES：過繼細(xì)胞治療惡性膠質(zhì)瘤過程中T細(xì)胞與造血干細(xì)胞之間的影響, objectType=article, longId=147732, objectId=af9314e73251, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af9314e73251, replyNumber=0, likeNumber=99, createdTime=2018-09-26, rootId=0, userName=apoenzyme, userId=7dc7399, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af9314e73251, moduleTitle=CLIN CANCER RES：過繼細(xì)胞治療惡性膠質(zhì)瘤過程中T細(xì)胞與造血干細(xì)胞之間的影響, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=af9314e73251)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2018111, encodeId=4a9d201811161, content=<a href='/topic/show?id=974294121a5' target=_blank style='color:#2F92EE;'>#過繼細(xì)胞治療#</a>, objectTitle=CLIN CANCER RES：靶向腫瘤脈管系統(tǒng)增強(qiáng)免疫檢查點(diǎn)抑制劑聯(lián)合過繼細(xì)胞治療療效, objectType=article, longId=138350, objectId=0e35138350d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e35138350d8, replyNumber=0, likeNumber=96, createdTime=2019-03-21, rootId=0, userName=apoenzyme, userId=7dc7399, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e35138350d8, moduleTitle=CLIN CANCER RES：靶向腫瘤脈管系統(tǒng)增強(qiáng)免疫檢查點(diǎn)抑制劑聯(lián)合過繼細(xì)胞治療療效, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=0e35138350d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2018110, encodeId=52852018110aa, content=<a href='/topic/show?id=974294121a5' target=_blank style='color:#2F92EE;'>#過繼細(xì)胞治療#</a>, objectTitle=JCI Insight：Th17細(xì)胞：腫瘤過繼細(xì)胞治療的又一利器！, objectType=article, longId=96237, objectId=66169623e20, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66169623e20, replyNumber=0, likeNumber=101, createdTime=2017-09-06, rootId=0, userName=apoenzyme, userId=7dc7399, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66169623e20, moduleTitle=JCI Insight：Th17細(xì)胞：腫瘤過繼細(xì)胞治療的又一利器！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=66169623e20)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
